Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2012-03-09 Director's Dealing
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2012-03-09 English
FORM 4
Director's Dealing
2012-03-09 English
OCULUS INNOVATIVE SCIENCES, INC.
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content specifically discusses compliance with NASDAQ listing rules regarding market value of listed securities and the resolution of a prior non-compliance issue. It does not contain financial statements or detailed financial data, nor is it an annual or quarterly report. The document is relatively short (3818 characters) and serves as a regulatory announcement about listing compliance status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-03-06 English
FORM 10-Q
Interim / Quarterly Report Q3 2012
2012-02-10 English
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 7, 2012, by Oculus Innovative Sciences, Inc. The content focuses on a notification from NASDAQ regarding the company's failure to meet listing requirements and the potential for delisting if compliance is not regained. The document does not contain financial statements or detailed financial analysis but is an official announcement about the company's listing status. The key section is 'Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,' which clearly indicates this is a delisting announcement. The document length is 4596 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Delisting Announcement (DLST).
2012-02-10 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) and includes detailed information about the offering of common stock shares, use of proceeds, risk factors, company background, and regulatory status. It is a formal disclosure related to a securities offering, specifically describing the terms of the offering and updating information from a previously filed shelf registration statement. The document is not a financial report, earnings release, or management discussion, but rather a capital markets disclosure related to fundraising and issuance of shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full prospectus supplement, not just an announcement or a brief notice.
2012-02-08 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.